2 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
as atypical antipsychotics with a clean profile Elicits in vivo effects within 15 minutes of administration and dissipates in 16 hours Effects are robust
8-K
EX-1.1
OVID
Ovid Therapeutics Inc
26 Aug 20
Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock
4:10pm
limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws, or any permit, license
- Prev
- 1
- Next